33 completed, 12 terminated, 7 recruiting, 3 unknown. 59 Phase 1, 21 Phase 2.
Follow Peripheral T-cell Lymphoma: new trials by email Literature Review of Peripheral T-cell Lymphoma trials Research Report on Peripheral T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 96 | 2026-03-02 | 2026-04-13 |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas C7R.CD30.CAR-EBVST cells - CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Phase 1 | Recruiting | Baylor College of Medicine | 90 | 2025-10-27 | 2026-10-02 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended) - Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 176 | 2025-08-15 | 2026-07-29 |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System BITR2101 - NHL, Cutaneous T Cell Lymphoma | Phase 1 | Not yet recruiting | Boston Immune Technologies and Therapeutics | 37 | 2025-08-01 | 2025-07-08 |
| A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies CHT101 - Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL) | Phase 1 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 24 | 2025-03-31 | 2025-04-06 |
| Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma chidamide and golidocitinib - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 45 | 2024-12-30 | 2025-01-03 |
| Golidocitinib Plus CHOP in Newly Diagnosed PTCL Golidocitinib plus CHOP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 68 | 2024-09-01 | 2024-12-18 |
| Linperlisib Combined With Chidamide in Patients With PTCL Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Yanyan Liu | 134 | 2024-05-25 | 2025-12-05 |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-12-22 | 2024-05-14 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma Linperlisib in combination with CHOP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Sun Yat-sen University | 44 | 2023-08-15 | 2026-09-16 |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP) - Peripheral T-cell Lymphoma | Phase 1 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 18 | 2022-07-07 | 2022-07-14 |
| Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin - Treatment, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2022-05-01 | 2022-07-01 |
| PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Parsaclisib, Chidamide - Peripheral T-Cell Lymphoma | Phase 1 | Terminated | Henan Cancer Hospital | 12 | 2022-02-20 | 2025-12-02 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab - Peripheral T-cell Lymphoma, NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 56 | 2020-08-18 | 2026-01-05 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer SEA-TGT, sasanlimab, brentuximab vedotin - Non-small Cell Lung Cancer, Gastric Carcinoma | Phase 1 | Terminated | Seagen Inc. | 133 | 2020-05-29 | 2025-02-10 |
| A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma AK104 - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Akeso | 6 | 2020-05-15 | 2022-10-19 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Romidepsin, Busulfan, Fludarabine - Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 23 | 2017-12-08 | 2025-09-19 |
Showing 20 of 59. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (59) · Lymphoma, T-Cell, Cutaneous (23) · Lymphoma, Extranodal NK-T-Cell (22) · Lymphoma, Large B-Cell, Diffuse (22) · Lymphoma, Large-Cell, Anaplastic (22) · Immunoblastic Lymphadenopathy (21) · Lymphoma, Non-Hodgkin (21) · Mycosis Fungoides (21) · Sezary Syndrome (20) · Leukemia, Lymphocytic, Chronic, B-Cell (19) · Lymphoma, Follicular (19) · Lymphoma, Mantle-Cell (19) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (19) · Burkitt Lymphoma (18) · Lymphoma, B-Cell, Marginal Zone (18)
Hemic and Lymphatic Diseases (59) · Immune System Diseases (59) · Immunoproliferative Disorders (59) · Lymphatic Diseases (58) · Lymphoproliferative Disorders (58) · Neoplasms by Histologic Type (58) · Neoplasms (57) · Lymphoma, T-Cell (55) · Lymphoma (52) · Lymphoma, Non-Hodgkin (38) · Hematologic Diseases (31) · Leukemia, Lymphoid (29) · Leukemia (28) · Disease Attributes (23) · Pathologic Processes (23)
Cyclophosphamide (6) · Doxorubicin (5) · Prednisone (5) · Vincristine (5) · Etoposide (4) · Lenalidomide (4) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (4) · fludarabine phosphate (4) · Dexamethasone (3) · Gemcitabine (3) · Peripheral Blood Stem Cell Transplantation (3) · romidepsin (3) · 10-propargyl-10-deazaaminopterin (2) · Azacitidine (2) · Bendamustine Hydrochloride (2)
National Cancer Institute (NCI) (7) · Fred Hutchinson Cancer Center (3) · Acrotech Biopharma Inc. (2) · City of Hope Medical Center (2) · Massachusetts General Hospital (2) · Peking Union Medical College Hospital (2) · Solasia Pharma K.K. (2) · Tianjin Medical University Cancer Institute and Hospital (2) · AbbVie (prior sponsor, Abbott) (1) · Aileron Therapeutics, Inc. (1) · Akeso (1) · Amir Mortazavi (1) · Antengene Corporation (1) · Aptevo Therapeutics (1) · Asana BioSciences (1)
United States (37) · China (13) · Canada (5) · Japan (4) · Italy (3) · Argentina (1) · Australia (1) · France (1) · Germany (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Jeremy Abramson, MD (2) · Aaron R Mangold, M.D. (1) · Adam Petrich, MD (1) · Ajay Gopal (1) · Ali Moiin, MD (1) · Amir Mortazavi, MD (1) · Andres Forero-Torres, MD (1) · Ann F Mohrbacher, MD (1) · Anthony J Reiman (1) · Auris O Huen, MD, PharmD (1) · Barbara Pro, MD (1) · Brad Haverkos, M.D. (1) · Brenda Sandmaier (1) · Christiane Querfeld, M.D., Ph.D. (1) · Craig Reeder, M.D. (1)
PMID 32499241, PMID 33051668, PMID 22259028, PMID 23393050, PMID 24474568, PMID 25605368, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28771889, PMID 29292843, PMID 29363235, PMID 29475723, PMID 29572391, PMID 30301414, PMID 30562587, PMID 31388792, PMID 33236943, PMID 33492438, PMID 33602316, PMID 34230007, PMID 40292284, PMID 41779512, PMID 42438166, PMID 42827632
P30CA015704 (3), U01CA097452 (2), 2019 (1), P01CA018029 (1), P01CA044991 (1), P01CA078902 (1), P30CA012197 (1), P30CA016058 (1), P30CA016672 (1), P30CA021765 (1), P30CA036727 (1), P50CA136411 (1), U01CA062461 (1), U01CA121947 (1), U01CA132194 (1)